SeaStar Medical (ICU) announced that it has successfully reached the halfway point in the NEUTRALIZE-AKI pivotal clinical trial, enabling a per protocol prespecified interim analysis by the trial’s independent Data Safety Monitoring Review Board, DSMB. SeaStar Medical anticipates the DSMB will report its findings to the company in the third quarter of 2025. “We are very pleased to reach this important enrollment milestone in the NEUTRALIZE-AKI pivotal trial,” stated Eric Schlorff, CEO of SeaStar Medical. “Kevin and his team have done an incredible job activating nationally recognized clinical trial sites, such as Cleveland Clinic, Mayo Clinic, and Stanford Medical Center. These and our other clinical sites are clearly aware of the high unmet need of these patients, and we are grateful for their active participation in the trial.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICU:
- SeaStar Medical files to sell 3.53M shares of common stock for holders
- SeaStar Medical granted two new BDD for SCD therapy by FDA
- SeaStar Medical Holdings: Buy Rating Driven by Clinical Milestones and Market Expansion Opportunities
- SeaStar Medical Reports 2024 Financial Results and Progress
- Is ICU a Buy, Before Earnings?
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue